Report Overview

The EU Attention deficit hyperactivity disorder Therapeutics market size stood at round USD 2.93 billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period

Attention deficit hyperactivity disorder (ADHD), is one of the most common neurological/psychiatric disorders among children and adolescents. ADHD is commonly observed in children as compared to adolescents. ADHD is also described as a hyperkinetic disorder/ attention deficit disorder or neuropsychiatric disorder. The exact cause for the ADHD is not clear but, expected to be resulted due to genetic factors and environmental influences. ADHD results in improper functioning of the nervous system that led to attention deficit and hyperactivity/impulsiveness conditions. ADHD is characterized by certain symptoms include easy distraction & striving to maintain focus on one task, unable to remember things, impatience, and being continuously in motion, among others



Market Drivers

Increasing involvements from public organizations, rising public consciousness towards better health conditions, and the presence of effective therapeutics for the treatment of
ADHD are driving the growth of the attention deficit hyperactivity disorder therapeutics market in Europe.
However, the presence of stringent regulatory guidelines and the high cost of the medication for ADHD are expected to restrain the growth of the attention deficit hyperactivity disorder therapeutics market in Europe